JPMorgan’s favorite stocks heading into September

JPMorgan refreshed its monthly analyst focus list, adding biopharma firm PTC Therapeutics and manufacturing company Armstrong World Industries amid broader market optimism for a September Federal Reserve rate cut. PTC Therapeutics, up 16% year-to-date, was given a $68 price target, representing 38% upside, with analysts citing its phenylketonuria program's potential for $788 million in peak sales. Armstrong World Industries, which has soared 37% this year, was added with a $210 price target, lauded for its operational stability and innovation. The bank also added McCormick and ACV Auctions, while removing Roivant, BellRing Brands, Edgewise Therapeutics, and Carlisle from its top picks.

Analysis

JPMorgan has updated its analyst focus list, signaling a bullish stance on specific growth and value opportunities amidst broad market optimism fueled by expectations of a Federal Reserve rate cut. The inclusion of PTC Therapeutics (PTCT) is particularly noteworthy, given the stock has already appreciated 16% this year. JPMorgan projects an additional 38% upside with a $68 price target, a view supported by a prior Bank of America upgrade that highlighted the company's new phenylketonuria (PKU) program as a key catalyst capable of generating an estimated $788 million in peak risk-adjusted sales. Another significant addition is Armstrong World Industries (AWI), which has soared 37% in 2025. JPMorgan's analyst highlights AWI's evolution into a 'solutions-oriented, building performance company' through innovations like TEMPLOK and ProjectWorks, praising its strong margin stability amid market volatility and its potential for multiple expansion. The list refresh also included the additions of McCormick and ACV Auctions and the removal of Roivant, BellRing Brands, Edgewise Therapeutics, and Carlisle, indicating a strategic rotation toward companies with distinct operational strengths and clear growth catalysts.

Key Decisions for Investors

• The dual endorsements from JPMorgan and Bank of America for PTC Therapeutics, both with a $68 price target, signal strong institutional conviction in the company's PKU program, which investors should evaluate as a primary growth driver.
• For Armstrong World Industries, investors should consider the company's praised operational stability and margin resilience alongside its strategic shift toward innovative, value-added solutions, though the 7% upside to JPMorgan's price target suggests a more modest near-term return expectation compared to its recent performance.
• The removal of Roivant, BellRing Brands, Edgewise Therapeutics, and Carlisle from the focus list serves as a potential negative signal, prompting investors holding these names to reassess their investment thesis and monitor for any fundamental shifts.
• Given that market sentiment is buoyed by a nearly 90% priced-in probability of a Fed rate cut, investors should consider that much of this macro optimism may already be reflected in the valuations of growth-oriented stocks.